CN111534496B - GGPPS Directional single-point mutant protein GGPPS-154 - Google Patents
GGPPS Directional single-point mutant protein GGPPS-154 Download PDFInfo
- Publication number
- CN111534496B CN111534496B CN202010452355.XA CN202010452355A CN111534496B CN 111534496 B CN111534496 B CN 111534496B CN 202010452355 A CN202010452355 A CN 202010452355A CN 111534496 B CN111534496 B CN 111534496B
- Authority
- CN
- China
- Prior art keywords
- ggpps
- site
- amino acid
- protein
- mutated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/825—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P23/00—Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
The application belongs to the technical field of tobacco genetic engineering, and particularly relates to GGPPS directional mutant protein. The three sites 154, 161 and 218 of the existing GGPPS protein are positioned in the catalytic pocket of the enzyme, and the two sites 209 and 233 are positioned on the surface of the enzyme molecule; based on these five sites, the present application provides GGPPS series of targeted muteins, including: a series of single-site muteins, double-site muteins, triple-site muteins, four-site muteins, and five-site muteins. The inventor utilizes CAST technology to construct a small and fine mutant library, and the inventor conducts detailed analysis on the mutation type of the amino acid at a specific position through further screening and based on the requirement of directed evolution. Preliminary experiment results show that after the amino acid at a specific site is mutated, the synthesis amount of the beta-carotene is obviously improved, and a certain technical basis is laid for further cultivating new varieties of crops.
Description
Technical Field
The application belongs to the technical field of tobacco genetic engineering, and particularly relates to GGPPS directional mutant protein patent application matters.
Background
The carotenoid is an important plastid pigment, has important physiological action, is closely related to the growth and development and photosynthesis of plants, and influences the quality and the characters of crops. Geranylgeranyl diphosphate (GGPP) is a common precursor for carotenoids, the phytol side chains of chlorophyll and vitamin E, gibberellins, and diterpene phytochemicals. GGPP is produced by catalysis of geranylgeranyl diphosphate synthase (GGPP synthsase, GGPPS), and 3 molecules of isopentenyl pyrophosphate (IPP) and 1 molecule of allyl isomer dimethylallyl pyrophosphate (DMAPP) are condensed under the action of GGPPS to produce C20 GGPP.
GGPP is a starting substrate for carotenoid synthesis, and is catalyzed by Phytoene Synthase (PSY), a terminal enzyme of the carotenoid synthesis pathway, to form phytoene, which is used for carotenoid synthesis. A great deal of research demonstration on plant GGPPS gene family shows that the family members not only encode important enzyme proteins at the upstream of a terpene synthesis pathway, but also directly participate in regulating various pathways of plant terpene synthesis, and play a central role in regulation.
In the existing research, although the synthesis routes of carotenoids have been studied more, from the aspect of plant improvement, if the oriented breeding and cultivation can be realized by using the genetic engineering technology, the method is an important technical premise for realizing the maximum utilization of plants.
As one of the key technologies in synthetic biology, directed biological evolution technology has acquired the 2018 nobel prize on chemistry. The technology is widely used for the activity design of enzyme, and can effectively overcome the defects of natural enzyme in the aspects of environmental tolerance, stereo/regioselectivity, substrate specificity, catalytic efficiency, product inhibition and the like through directed evolution, so that the evolution process of thousands of years in the nature is completed in a laboratory in a short time.
In the development process of the directed evolution technology of the enzyme, when the traditional directed evolution is carried out, such as error-prone PCR, DNA mixed group, sequence saturation mutation, random initiation of in vitro recombination and other technologies, the defects of low mutation efficiency, large screening workload and the like exist, and the application of the in vitro directed evolution of enzyme molecules is restricted. The combined active-site mutation strategy (CAST) is a relatively new directed evolution mutation strategy, and the technology is based on the structural information of protein, firstly, by means of the simulation basis of a computer, then, amino acid residues which have direct interaction with a substrate are selected around an enzyme catalytic active center, and the screening scale of a mutant library is reduced by constructing a small and fine mutant library.
Generally, although the directed evolution technology can accelerate the evolution process of crop genes and provide high-quality genes for improving the quality of crops, the directed evolution technology is not used for the transformation of plant genes at present because the development time is short and other technical problems exist.
Tobacco is one of model crops for genetic engineering research, and meanwhile, the carotenoid content in tobacco directly influences the quality and the character of the tobacco. Therefore, if the directional evolution can be combined to carry out the directional transformation on the terpene synthetic genes of the tobacco, the method has very important application significance for accelerating the tobacco breeding, and simultaneously, a certain technical foundation can be laid for the genetic breeding of other crops.
Disclosure of Invention
Through the research on the structure of geranylgeranyl diphosphate synthase (GGPP synthsase, GGPPS) enzyme and the combination of the directed evolution technology, the application aims to provide a plurality of GGPPS and tobacco GGPPS genes with better enzyme activity, thereby providing a new technical thought for tobacco breeding and new tobacco variety cultivation and simultaneously laying a certain technical foundation for breeding and variety improvement of other crops.
The technical solution adopted in the present application is detailed as follows.
In the process of researching the existing GGPPS structure, the inventor thinks that the 154 th site, the 161 th site and the 218 th site of the existing GGPPS protein (the corresponding gene sequence is NM-001325177.1) are positioned in a catalytic pocket of enzyme, so after the directional mutation is carried out on the amino acids of the three sites, the combination of a substrate and the enzyme activity pocket is facilitated, and the enzyme activity performance of GGPPS is improved; the 209 th site and the 233 th site are positioned on the surface of enzyme molecules, and after directional mutation is carried out on the amino acids of the two sites, GGPPS homodimers are favorably formed, so that the stability of the protein is enhanced; based on the five sites, the inventors provide the GGPPS series of directional mutant proteins, which include: the specific introduction of the series of single-site mutant proteins, the series of double-site mutant proteins, the series of three-site mutant proteins, the series of four-site mutant proteins and the series of five-site mutant proteins is described as follows.
Single site mutations:
GGPPS directional single-point mutant protein GGPPS-154, compared with the existing tobacco GGPPS protein, val (V) amino acid at the 154 th position is mutated into neutral amino acid Ala (A) or cysteine Cys (C);
compared with the existing tobacco GGPPS protein, the GGPPS directional single-point mutant protein GGPPS-161 has the advantages that the Ile (I) amino acid at the 161 th site is mutated into neutral aliphatic amino acid Leu (L) or is mutated into amino acid Met (M) containing sulfydryl;
GGPPS is a directional single-point mutant protein GGPPS-209, and compared with the existing tobacco GGPPS protein, the 209 th Ile (I) amino acid of the GGPPS protein is mutated into a basic amino acid Lys (K) and a hydroxyl-containing amino acid Ser (S), or is mutated into any one of aspartic acid Asp (D), asparagine Asn (N), alanine Ala (A) or proline Pro (P);
GGPPS directional single point mutant protein GGPPS-218, compared with the existing tobacco GGPPS protein, the 218 th Phe (F) amino acid of the GGPPS directional single point mutant protein is mutated into aromatic amino acid tyrosine Tyr (Y) or leucine Leu (L);
GGPPS directional single-point mutant protein GGPPS-233, compared with the existing tobacco GGPPS protein, the 233 th amino acid Val of which is mutated into the acidic amino acid Glu (E) or tyrosine Tyr (Y);
the amino acid sequence of the existing tobacco GGPPS protein is shown in SEQ ID NO. 1.
In the two-site mutation:
on the basis of the unit mutation, the mutant protein formed by combining any two of the unit sites shows better enzyme activity effect, and specifically, the double-site mutant protein is, for example:
GGPPS directional double-site mutant protein 209-233, and compared with the existing tobacco GGPPS protein, ile amino acid 209 and Val amino acid 233 are mutated simultaneously; the 209 th Ile (I) amino acid is mutated into any one of basic amino acid Lys (K), amino acid Ser (S) containing hydroxyl, aspartic acid Asp (D), asparagine Asn (N), alanine Ala (A) or proline Pro (P), and the 233 th Val amino acid is mutated into acidic amino acid Glu (E) or tyrosine Tyr (Y);
that is, the GGPPS directed double site mutant protein 209-233 has the following combination of sites 209 and 233: 209K-233E, 209S-233E, 209P-233E, 209S-233Y, 209P-233Y, or the like.
In the three-site mutation:
on the basis of the unit mutation, mutant proteins formed by any three-site combination show better enzyme activity effect, and specifically, the two-site mutant proteins are, for example:
the directional three-point mutant protein GGPPS-154-161-218 has simultaneous mutation of Val amino acid in 154 th position, ile amino acid in 161 th position and Phe amino acid in 218 th position compared with the existing tobacco GGPPS protein; the Val (V) amino acid at the 154 th position is mutated into a neutral amino acid Ala (A) or is mutated into a cysteine Cys (C); the Ile (I) amino acid at the 161 th position is mutated into neutral aliphatic amino acid Leu (L) or is mutated into amino acid Met (M) containing sulfydryl; the 218 th Phe (F) amino acid is mutated into an aromatic amino acid tyrosine Tyr (Y) or into leucine Leu (L);
namely, the GGPPS directional three-point mutant protein GGPPS-154-161-218 is combined as follows: 154A-161M-218L, 154A-161M-218Y, 154A-161L-218L, 154A-161L-218Y, 154C-161M-218L, 154C-161M-218Y, 154C-161L-218L, 154C-161L-218Y, and the like.
In the five-site mutation:
on the basis of the unit mutation, the mutant protein formed by any mutation combination of five sites shows better enzyme activity effect, and specifically, the double-site mutant protein is, for example:
compared with the existing tobacco GGPPS protein, the directional five-site mutant protein GGPPS of the enzyme pocket and the surface of the enzyme molecule simultaneously mutates Val amino acid at position 154, ile amino acid at position 161, ile amino acid at position 209, phe amino acid at position 218 and Val amino acid at position 233;
the five-site mutant protein GGPPS combination is as follows: 154A-161M-209K-218Y-233E, 154A-161M-209S-218Y-233E, 154A-161L-209S-218Y-233E, or 154A-161L-209K-218Y-233E, and the like.
The GGPPS directional mutant protein is applied to pigment synthesis, and is used for catalyzing GGPP to synthesize beta-carotene.
The novel crop variety breeding method based on the GGPPS series directional mutant protein coding gene is characterized in that the content of pigment substances in crops can be adjusted (increased) by recombining the GGPPS series directional mutant protein coding gene into a crop genome by using a genetic engineering technical means;
the pigment substance is beta-carotene;
the crops are as follows: tobacco, pepper, tomato, rice, corn, wheat, potato, castor-oil plant, apple, cucumber, watermelon, carrot, banana, orange, grape, coffee, ginkgo, salvia, chrysanthemum or rubber tree, etc.
GGPP is used as a precursor substance of downstream carotenoid, and the inventors show that 154, 161, 209, 218 and 233 are key sites through structural analysis of key amino acid sites of an enzyme active pocket of GGPPS. Furthermore, the inventor utilizes CAST technology to construct a small and fine mutant library, thereby overcoming the defects of low mutation rate, large screening amount and the like in the traditional directed evolution screening process. Through further screening and based on the requirement of directed evolution, the inventors have conducted detailed analysis on the types of amino acid mutations at specific sites. Preliminary experiment results show that after the amino acid at a specific site is mutated, the synthesis amount of the beta-carotene is obviously improved, and a certain technical basis is laid for further cultivating new varieties of crops.
Drawings
FIG. 1 is a bacterial color experiment of GGPPS-154 mutant, in which: a double plasmid bacteria color experiment, PAC-94N plasmid contains PSY, PDS and LCY-B three genes, IPP and DMAPP can be synthesized in Escherichia coli, but GGPP can not be produced, after GGPPS plasmid with enzyme activity and PAC-94N are jointly transformed into Escherichia coli, beta-carotene can be catalytically produced in Escherichia coli, and Escherichia coli is transformed from white to yellow; B. in the GGPPS-154 single-site mutation bacterial color experiment, the 154 th amino acid site is mutated, after the 154 th amino acid site and PAC-94N double plasmids are jointly transformed into escherichia coli BL21 (DE) 3, the color of the bacterial liquid is obviously changed after IPTG induction, the lower graph is the light absorption value at OD440, and empty pET32b is used as negative control, so that the light absorption value of the mutant at OD440 is obviously improved compared with wild type GGPPS;
FIG. 2 shows bacterial color experiments of GGPPS-161 mutant, wherein A is the same as that in FIG. 1A and is a synthetic schematic diagram, and B is bacterial color experiments of single-site mutation of GGPPS-161;
FIG. 3 is the bacterial color experiment of GGPPS-218 mutant, wherein, the A picture is the same as the A picture of FIG. 1 and is a synthetic principle picture, and the B picture is the bacterial color experiment of single-site mutation of GGPPS-218;
FIG. 4 shows bacterial color experiments of GGPPS-209 mutant, wherein A is the same as that in FIG. 1A and is a synthetic principle diagram, and B is bacterial color experiments of single-site mutation of GGPPS-209;
FIG. 5 shows bacterial color experiments of GGPPS-233 mutant, wherein A is the same as FIG. 1A and is a synthetic schematic diagram, and B is bacterial color experiments of single-site mutation of GGPPS-233;
FIG. 6 shows bacterial color experiments of GGPPS-154/161/218 mutant, in which FIG. A is the same as FIG. 1A and is a synthetic schematic diagram, and FIG. B shows bacterial color experiments of GGPPS-154/161/218 three-site combined mutation;
FIG. 7 shows bacterial color experiments of GGPPS-209/233 mutant, wherein A is the same as that in FIG. 1A and is a synthetic schematic diagram, and B is bacterial color experiments of GGPPS-209/233 two-site combined mutation;
FIG. 8 shows bacterial color experiments of GGPPS-154/161/209/218/233 mutant, wherein the A picture is the same as the A picture in FIG. 1, and is a synthetic schematic diagram, and the B picture is bacterial color experiments of combined mutation of five sites of GGPPS-154/161/209/218/233.
FIG. 9 is a comparison of GGPPS-154 and the main stream crop GGPPS loci, in which: hot pepper (cagggpps 1), potato (StGGPPS 1), wheat (tagggpps 1), corn (ZmGGPPS 1), salvia miltiorrhiza (SmGGPPS 1), coffee (CanGGPPS 1), carrot (DcGGPPS 1), grape (VvGGPPS), cucumber (CsaGGPPS), watermelon (ClGGPPS), apple (MdGGPPS 1), orange (csigpps), rubber tree (HbGGPPS), chrysanthemum (CmGGPPS), rice (OsGGPPS 1), tomato (SlGGPPS 1), castor bean (rcgggpps), banana (magggpps) and ginkgo biloba (GbGGPPS).
Detailed Description
The present application is further explained below with reference to the drawings and examples.
Example 1
Since the acquisition of the existing geranylgeranyl diphosphate synthase (GGPPS) gene is the basis of the analysis of the relevant sequences and the directed evolution mutation, this example is summarized below with respect to the cloning acquisition of the existing geranylgeranyl diphosphate synthase (GGPPS) gene.
First, based on the gene sequence shown in GenBank accession No. NM-001325177.1, primer sequences for PCR amplification were designed as follows:
a forward primer: 5 'atgagattattatgaatcttgt-3',
reverse primer: 5 'attttcacgataagcaatgate-doped 3';
carrying out PCR amplification by taking cDNA of K326 leaves of tobacco as a template;
carrying out electrophoresis detection on the PCR amplification product, recovering and purifying, and connecting the recovered and purified PCR product with pGEMT plasmid;
subsequently, the ligation product was transformed into E.coli DH 5. Alpha. Competent cells, and after overnight culture, positive clones were selected and identified to obtain the recombinant correct cloning plasmid pGEMT-GGPPS.
In order to facilitate the subsequent expression of GGPPS, pET-32b (+) plasmids are utilized, and the inventor further constructs a recombinant expression vector, wherein the specific process is as follows:
first, a pair of primer sequences containing Nde I and Xho I cleavage sites was designed as follows:
a forward primer: 5 'gctaatccatatgGAGCAATTCAATTTCAAAACT-3',
reverse primer: 5 'cagctccgaggaATTTTCACGATAAGCAATGTAAT-3';
then, using the clone plasmid pGEMT-GGPPS as a template to carry out PCR amplification so as to obtain a GGPPS gene, and recycling and purifying PCR amplification products;
subsequently, carrying out Nde I and Xho I double enzyme digestion on the GGPPS gene product obtained by PCR amplification and the pET-32b (+) plasmid respectively, and recovering enzyme digestion products for connection;
finally, the ligation product is transformed into DH5 alpha competent cells, after overnight culture, positive clones are selected for identification, and the correctly identified recombinant expression plasmid vector is renamed as: pET-32b (+) -GGPPS.
Example 2
In order to facilitate the detection and analysis of relevant mutation sites, the present application has been experimentally verified using a geranylgeranyl diphosphate synthase (GGPPS) recombinant engineered strain, and therefore, the construction process of this engineered strain is briefly described below in this example.
First, the recombinant vector pET-32b (+) -GGPPS constructed in example 1 was co-transformed with PAC-94N plasmid to express the strain E.coli BL21 (DE 3), and meanwhile, the empty vector pET-32b (+) was co-transformed with PAC-94N plasmid to serve as a negative control strain;
subsequently, after overnight culture, positive clones were selected for identification, and strains of positive clones that were sequenced correctly were either preserved or subjected to further beta-carotene content testing.
The principle of detecting the content of the beta-carotene comprises the following steps: coli cannot produce GGPP by itself, and PAC-94N plasmid contains all genes of a beta-carotene synthesis pathway but does not contain geranylgeranyl diphosphate synthase encoding genes, so that when the recombinant vector pET-32b (+) -GGPPS and the PAC-94N plasmid are co-transformed, the strain which can catalytically produce GGPP is changed from white to yellow, the strain with stronger enzyme activity has deeper yellow, and the absorbance value of OD440 is further measured by a spectrophotometer, so that the content of the final product beta-carotene can be measured.
Example 3
Since no crystal structure is reported in tobacco GGPPS, the inventors have performed homologous modeling on the enzyme based on the amino acid sequence in order to analyze the protein. During modeling, the optimal template was 3kro, the score was 0.993 (TM-score was used to measure the degree of matching between two protein structure models, a score from 0 to 1,1 means perfect match), the Root Mean Square Deviation (RMSD) was 0.36 a, the sequence Identity (IDEN) was 74.9%, and the protein structure coverage (Cov) was 99.7%.
The substrates C5-DMAPP, C10-GPP, C15-FPP were docked to the GGPPS catalytic pocket using the Rosetta docking program, respectively. The binding mode of the receptor small molecule compound is predicted by searching the optimal binding position for the action of the receptor small molecule compound and the enzyme. The final analysis results show that: the 154 th site, the 161 th site and the 218 th site are positioned in a catalytic pocket of the enzyme, the binding capacity of a substrate and an enzyme activity pocket can be further improved after amino acid substitution, and the sites participate in enzyme activity regulation and control; and the 209 th and 233 th amino acid sites are positioned on the surface of the enzyme molecule, so that the protein is favorable for forming a dimer.
It should be noted that, the existing GGPPS consists of 296 amino acids, and the specific sequence is shown in SEQ ID No.1, which is as follows:
EQFNFKTYVAEKAISVNKALDEAVIVKDPPVIHEAMRYSLLAGGKRVRPMLCLAACELVGGDQSNAMPAACAVEMIHTMSLIHDDLPCMDNDDLRRGKPTNHKVYGEDVAVLAGDSLLAFAFEYIATATAGVSPSRILAAIGELAKSIGTEGLVAGQVADIACTGNPNVGLDTLEFIHIHKTAALLEASVVLGAILGGGTDEEVEKLRIFARCIGLLFQVVDDILDVTKSSEVLGKTAGKDLAVDKTTYPKLLGLEKAKEFAAELNRDAKQQLVEFDPHKAAPLIALADYIAYREN
the gene for coding GGPPS consists of 888 nucleotides, and the specific sequence is shown as SEQ ID No.2, and specifically comprises the following steps:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
based on the above analysis, the inventors further constructed a GGPPS saturation mutant library for these 5 loci, and the specific construction process is briefly described below.
First, degenerate primer sequences were designed based on the above 5 sites as follows:
V154-F:5’-ggaactgaagggttannkgctggacaagtagcg-3’,
I161-F: 5’-ggacaagtagcggatnnkgcttgtactggtaac-3’,
I209-F: 5’-gtggagaaattgaggnnkttcgcgagatgtatt-3’,
F218-F: 5’-tgtattggattattgnnkcaagtagtagatgat-3’,
V233-F: 5’-acaaagtcgtcggagnnkctcggaaaaaccgcc-3’,
general-R: 5’-cacgataagcaatgtaatccg-3’;
subsequently, whole plasmid PCR was performed using pET-32b (+) -GGPPS constructed in example 1 as a template, and then V154-F, I161-F, I209-F, F218-F and V233-F as forward primers and general-R as reverse primers, respectively;
and then, dpnI digestion is carried out on the PCR amplification product, the digested product and PAC-94N double plasmid are jointly transformed into E.coli BL21 (DE 3) competent cells, and after the transformation is finished, the bacterial liquid is coated on a flat plate containing 100 mu g/L ampicillin and 34 mu g/L chloramphenicol, and finally, a saturated mutation library is obtained.
For further screening, positive single clones were selected, cultured overnight in 20ml of LB liquid medium containing ampicillin (100. Mu.g/L) and chloramphenicol (34. Mu.g/L), and induced to express at 18 ℃ for 18 hours with IPTG at a final concentration of 0.1mM, after completion of the culture, the supernatant was centrifuged and discarded, photographed, and resuspended in 3ml of acetone, and then the OD440 value was measured.
And finally screening and determining the mutant with obviously enhanced absorbance by adopting the high-throughput screening method and further sequencing. The results show that when: the Val (V) amino acid at the 154 th position is mutated into a neutral amino acid Ala (A) or is mutated into a cysteine Cys (C); the Ile (I) amino acid at the 161 th position is mutated into neutral aliphatic amino acid Leu (L) or is mutated into amino acid Met (M) containing sulfydryl; mutation of Ile (I) amino acid at position 209 to basic amino acid Lys (K), amino acid Ser (S) containing hydroxyl, aspartic acid Asp (D), asparagine Asn (N), alanine Ala (A) or proline Pro (P); phe (F) amino acid 218 is mutated into aromatic amino acid tyrosine Tyr (Y) or leucine Leu (L); when the 233 th amino acid Val is mutated into the acidic amino acid, the acidic amino acid is Glu (E) or tyrosine Tyr (Y); the geranylgeranyl diphosphate synthase GGPPS of tobacco has obvious change.
For position 154:
when the 154 site is mutated to A, the amino acid sequence is as follows:
EQFNFKTYVAEKAISVNKALDEAVIVKDPPVIHEAMRYSLLAGGKRVRPMLCLAACELVGGDQSNAMPAACAVEMIHTMSLIHDDLPCMDNDDLRRGKPTNHKVYGEDVAVLAGDSLLAFAFEYIATATAGVSPSRILAAIGELAKSIGTEGLAAGQVADIACTGNPNVGLDTLEFIHIHKTAALLEASVVLGAILGGGTDEEVEKLRIFARCIGLLFQVVDDILDVTKSSEVLGKTAGKDLAVDKTTYPKLLGLEKAKEFAAELNRDAKQQLVEFDPHKAAPLIALADYIAYREN;
the corresponding base coding sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGCGGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT;
when the 154 site is mutated to C, the base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTATGCGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
for position 161:
when the 161 site is mutated to L, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATCTGGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 161 site is mutated to M, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATGGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
for position 218:
when the 218 site is mutated to L, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGCTGCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 218 site is mutated to Y, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTATCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
for site 209:
when the 209 th site is mutated to P, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGCCGTTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 209 th site is mutated to K, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGAAATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 209 th site is mutated to D, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGGATTTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 209 th site is mutated to N, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGAATTTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 209 th site is mutated to S, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGAGCTTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 209 site is mutated to A, the coding base sequence is as follows:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGGCGTTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGTGCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
for position 233:
when the 233 site is mutated to E, it encodes the base sequence:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGAACTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT
when the 233 site is mutated to Y, the coding base sequence is:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGTAGCTGGACAAGTAGCGGATATAGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGATATTCGCGAGATGTATTGGATTATTGTTTCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGTATCTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
other two-site, three-site or five-site specific base sequences can be referred to above, for example, for five-site mutant protein GGPPS-154A/161L/209S/218Y/233E, the amino acid sequence of which is:
EQFNFKTYVAEKAISVNKALDEAVIVKDPPVIHEAMRYSLLAGGKRVRPMLCLAACELVGGDQSNAMPAACAVEMIHTMSLIHDDLPCMDNDDLRRGKPTNHKVYGEDVAVLAGDSLLAFAFEYIATATAGVSPSRILAAIGELAKSIGTEGLAAGQVADLACTGNPNVGLDTLEFIHIHKTAALLEASVVLGAILGGGTDEEVEKLRSFARCIGLLYQVVDDILDVTKSSEELGKTAGKDLAVDKTTYPKLLGLEKAKEFAAELNRDAKQQLVEFDPHKAAPLIALADYIAYREN
in this case, the corresponding coding base sequence is:
GAGCAATTCAATTTCAAAACTTACGTAGCTGAAAAGGCTATTTCTGTAAATAAAGCTTTAGATGAGGCTGTTATAGTAAAAGACCCACCTGTGATCCACGAAGCAATGCGCTATTCACTTCTCGCCGGCGGCAAAAGAGTCCGACCGATGCTCTGCCTCGCCGCCTGCGAGCTCGTCGGCGGCGACCAATCCAACGCCATGCCGGCTGCTTGCGCCGTCGAGATGATCCACACTATGTCCCTCATTCACGACGATTTACCTTGTATGGATAACGACGATCTCCGCCGTGGAAAGCCGACGAACCACAAAGTCTACGGCGAGGACGTGGCGGTCCTCGCCGGAGACTCGCTCCTCGCTTTCGCCTTCGAGTACATCGCCACCGCTACCGCCGGAGTTTCACCGTCGAGGATCCTCGCCGCCATCGGCGAACTGGCGAAATCCATCGGAACTGAAGGGTTAGCGGCTGGACAAGTAGCGGATCTGGCTTGTACTGGTAACCCTAATGTTGGACTCGACACACTCGAATTCATTCACATACACAAAACGGCGGCGCTTCTAGAAGCTTCCGTAGTTCTCGGAGCAATCCTCGGCGGCGGAACAGATGAAGAAGTGGAGAAATTGAGGAGCTTCGCGAGATGTATTGGATTATTGTATCAAGTAGTAGATGATATACTCGATGTTACAAAGTCGTCGGAGGAACTCGGAAAAACCGCCGGAAAAGATTTGGCAGTAGATAAAACGACGTATCCAAAACTGCTGGGATTGGAAAAGGCTAAGGAATTTGCGGCGGAGCTCAACCGAGATGCTAAACAACAGCTGGTGGAATTTGATCCACACAAAGCTGCTCCCTTGATTGCTTTGGCGGATTACATTGCTTATCGTGAAAAT。
furthermore, the inventors have performed different combination type mutations at amino acid positions 154, 161, 209, 218 and 233, synthesized expression vectors with different combination mutations by using the existing genetic engineering technology, further constructed different strains by using the construction method of the geranylgeranyl diphosphate synthase (GGPPS) recombinant engineering strain in example 2, and examined the synthetic amount of beta-carotene. The specific test results are summarized below.
The results of the single-site experiments shown in FIGS. 1 to 5 show that:
when the 154 th Val is mutated into Ala or Cys, the 161 th Ile is mutated into Leu or Met, the 209 th Ile is mutated into Lys, ser, aspartic acid Asp, asparagine Asn, alanine Ala and proline Pro, the 218 th Phe is mutated into Leu or Tyr, and the 233 th Val is mutated into Glu or Tyr, the color of the thallus or the synthetic amount of the beta-carotene is obviously improved;
as shown in FIGS. 6 to 8, the results of the two-site, three-site and five-site experiments show that the color of the cells or the synthesis amount of beta-carotene is obviously improved under the condition of different site combinations in a specific mutation direction.
The results show that the GGPPS enzyme activity can be better provided by aiming at the directional mutation evolution mode of a specific site, so that a good foundation is laid for further providing the beta-carotene content in crops.
Example 4
Based on the analysis and verification of example 3, the inventors further analyzed the GGPPS modification sites of the existing mainstream crops. The results of comparative analysis of amino acid sequences (as shown in FIG. 9, FIG. 9 shows only the 154-position comparison results) indicate that: similar to GGPPS of tobacco, pepper (cagggpps 1), potato (StGGPPS 1), wheat (tagggpps 1), corn (ZmGGPPS 1), salvia miltiorrhiza (SmGGPPS 1), coffee (CanGGPPS 1), carrot (DcGGPPS 1), grape (VvGGPPS), cucumber (csagpps), watermelon (ClGGPPS), apple (MdGGPPS 1), orange (csighbpps), rubber tree (GGPPS), chrysanthemum (CmGGPPS), rice (OsGGPPS 1), tomato (SlGGPPS 1), castor (rcgggpps), banana (magggpps), and ginkgo (GbGGPPS) are all conserved in 5 sites of GGPPS enzyme, and thus, mutation based on the same site is feasible, or the directional mutant protein obtained by the present application is directly utilized, and a new idea is provided for breeding new varieties of these mainstream crops.
SEQUENCE LISTING
<110> Zhengzhou tobacco institute of China tobacco general company
<120> GGPPS Directional Single-Point mutein GGPPS-154
<130> none
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 296
<212> PRT
<213> Nicotiana tabacum
<400> 1
Glu Gln Phe Asn Phe Lys Thr Tyr Val Ala Glu Lys Ala Ile Ser Val
1 5 10 15
Asn Lys Ala Leu Asp Glu Ala Val Ile Val Lys Asp Pro Pro Val Ile
20 25 30
His Glu Ala Met Arg Tyr Ser Leu Leu Ala Gly Gly Lys Arg Val Arg
35 40 45
Pro Met Leu Cys Leu Ala Ala Cys Glu Leu Val Gly Gly Asp Gln Ser
50 55 60
Asn Ala Met Pro Ala Ala Cys Ala Val Glu Met Ile His Thr Met Ser
65 70 75 80
Leu Ile His Asp Asp Leu Pro Cys Met Asp Asn Asp Asp Leu Arg Arg
85 90 95
Gly Lys Pro Thr Asn His Lys Val Tyr Gly Glu Asp Val Ala Val Leu
100 105 110
Ala Gly Asp Ser Leu Leu Ala Phe Ala Phe Glu Tyr Ile Ala Thr Ala
115 120 125
Thr Ala Gly Val Ser Pro Ser Arg Ile Leu Ala Ala Ile Gly Glu Leu
130 135 140
Ala Lys Ser Ile Gly Thr Glu Gly Leu Val Ala Gly Gln Val Ala Asp
145 150 155 160
Ile Ala Cys Thr Gly Asn Pro Asn Val Gly Leu Asp Thr Leu Glu Phe
165 170 175
Ile His Ile His Lys Thr Ala Ala Leu Leu Glu Ala Ser Val Val Leu
180 185 190
Gly Ala Ile Leu Gly Gly Gly Thr Asp Glu Glu Val Glu Lys Leu Arg
195 200 205
Ile Phe Ala Arg Cys Ile Gly Leu Leu Phe Gln Val Val Asp Asp Ile
210 215 220
Leu Asp Val Thr Lys Ser Ser Glu Val Leu Gly Lys Thr Ala Gly Lys
225 230 235 240
Asp Leu Ala Val Asp Lys Thr Thr Tyr Pro Lys Leu Leu Gly Leu Glu
245 250 255
Lys Ala Lys Glu Phe Ala Ala Glu Leu Asn Arg Asp Ala Lys Gln Gln
260 265 270
Leu Val Glu Phe Asp Pro His Lys Ala Ala Pro Leu Ile Ala Leu Ala
275 280 285
Asp Tyr Ile Ala Tyr Arg Glu Asn
290 295
<210> 2
<211> 888
<212> DNA
<213> Nicotiana tabacum
<400> 2
gagcaattca atttcaaaac ttacgtagct gaaaaggcta tttctgtaaa taaagcttta 60
gatgaggctg ttatagtaaa agacccacct gtgatccacg aagcaatgcg ctattcactt 120
ctcgccggcg gcaaaagagt ccgaccgatg ctctgcctcg ccgcctgcga gctcgtcggc 180
ggcgaccaat ccaacgccat gccggctgct tgcgccgtcg agatgatcca cactatgtcc 240
ctcattcacg acgatttacc ttgtatggat aacgacgatc tccgccgtgg aaagccgacg 300
aaccacaaag tctacggcga ggacgtggcg gtcctcgccg gagactcgct cctcgctttc 360
gccttcgagt acatcgccac cgctaccgcc ggagtttcac cgtcgaggat cctcgccgcc 420
atcggcgaac tggcgaaatc catcggaact gaagggttag tagctggaca agtagcggat 480
atagcttgta ctggtaaccc taatgttgga ctcgacacac tcgaattcat tcacatacac 540
aaaacggcgg cgcttctaga agcttccgta gttctcggag caatcctcgg cggcggaaca 600
gatgaagaag tggagaaatt gaggatattc gcgagatgta ttggattatt gtttcaagta 660
gtagatgata tactcgatgt tacaaagtcg tcggaggtgc tcggaaaaac cgccggaaaa 720
gatttggcag tagataaaac gacgtatcca aaactgctgg gattggaaaa ggctaaggaa 780
tttgcggcgg agctcaaccg agatgctaaa caacagctgg tggaatttga tccacacaaa 840
gctgctccct tgattgcttt ggcggattac attgcttatc gtgaaaat 888
Claims (4)
- GGPPS directional single-point mutant protein GGPPS-154 is characterized in that compared with the existing tobacco GGPPS protein, val amino acid at the 154 th position is mutated into neutral amino acid Ala or is mutated into cysteine Cys;the amino acid sequence of the existing tobacco GGPPS protein is shown in SEQ ID NO. 1.
- 2. The use of the GGPPS directed single point mutant protein GGPPS-154 in pigment synthesis according to claim 1, for catalyzing the synthesis of beta-carotene from GGPP.
- 3. The recombinant expression vector pET-32b (+) -GGPPS for expressing the GGPPS directional single-point mutant protein GGPPS-154 of claim 1, wherein a gene coding for the directional single-point mutant protein GGPPS-154 is recombined in a pET-32b (+) plasmid.
- 4. The GGPPS directed single-point mutant protein GGPPS-154 of claim 1 is applied to the cultivation of tobacco varieties, and is characterized in that the site directionally designed by GGPPS-154 is used for modifying the tobacco GGPPS gene or recombining the directed single-point mutant protein GGPPS-154 into the tobacco genome by using a genetic engineering technical means to adjust the content of pigment substances in tobacco;the pigment is beta-carotene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010452355.XA CN111534496B (en) | 2020-05-26 | 2020-05-26 | GGPPS Directional single-point mutant protein GGPPS-154 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010452355.XA CN111534496B (en) | 2020-05-26 | 2020-05-26 | GGPPS Directional single-point mutant protein GGPPS-154 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111534496A CN111534496A (en) | 2020-08-14 |
CN111534496B true CN111534496B (en) | 2022-10-28 |
Family
ID=71974044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010452355.XA Active CN111534496B (en) | 2020-05-26 | 2020-05-26 | GGPPS Directional single-point mutant protein GGPPS-154 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111534496B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3120684B2 (en) * | 1995-02-14 | 2000-12-25 | トヨタ自動車株式会社 | Mutant farnesyl diphosphate synthase that synthesizes geranylgeranyl diphosphate and DNA encoding the same |
JP3562280B2 (en) * | 1997-12-16 | 2004-09-08 | トヨタ自動車株式会社 | Geranyl diphosphate synthase gene |
CN101475946B (en) * | 2009-01-16 | 2013-06-26 | 上海师范大学 | Geranylgeranyl diphosphate synthase gene in salvia root, and encoding protein and use thereof |
JP5787341B2 (en) * | 2009-11-19 | 2015-09-30 | 国立大学法人 千葉大学 | Screening method for terpene synthase gene |
-
2020
- 2020-05-26 CN CN202010452355.XA patent/CN111534496B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111534496A (en) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107686840B (en) | Pears transcription factor PyERF3 and its recombinant expression carrier and application | |
CN112695047A (en) | Method for producing fucoxanthin by using mutant strain expressing exogenous pyruvate phosphate dikinase in phaeodactylum tricornutum | |
Min et al. | Genome-wide identification and characterization of the aquaporin gene family in Medicago truncatula | |
CN111500551B (en) | GGPPS directed single point mutant protein GGPPS-218 | |
CN111593032B (en) | Directional five-site mutant protein GGPPS on enzyme pocket and enzyme molecule surface | |
CN107955067B (en) | Two MYB transcription factors involved in peach flavonol biosynthesis regulation and control and application thereof | |
CN113957086A (en) | Application of SlBIN2 gene in regulation and control of tomato fruit ripening and carotenoid synthesis | |
CN111304228A (en) | Rubber tree mitochondrial hexokinase gene and encoding protein and application thereof | |
CN111534496B (en) | GGPPS Directional single-point mutant protein GGPPS-154 | |
CN111549009B (en) | Directional three-point mutant protein GGPPS-154-161-218 | |
CN111534497B (en) | GGPPS directed single point mutant protein GGPPS-161 | |
CN111549010B (en) | GGPPS directional double-site mutant protein 209-233 | |
CN107326035B (en) | Deubiquitinating enzyme gene UBP5 for regulating rice grain shape and leaf color and application thereof | |
CN108588098A (en) | Eucalyptus urophylla CAD genes and its application | |
Slugina et al. | Structural and functional diversification of SEPALLATA genes TM5 and RIN in tomato species (section Lycopersicon) | |
BR112015011990B1 (en) | RECOMBINANT POLYNUCLEOTIDE ENCODING A HOMEOBOX4 (WOX4) POLYPEPTIDE RELATED TO WUSCHEL FROM C. OLITORIUS AND C.CAPSULARIS, RECOMBINANT GENE CONSTRUCTION AND GENETICALLY MODIFIED PROKYOTIC TRANSFORMING COMPRISING RECOMBINANT POLYNUCLEOTIDE | |
CN111534499A (en) | GGPPS directed single point mutant protein GGPPS-233 | |
CN111718916A (en) | GGPPS directed single-point mutant protein and application thereof | |
US20110104806A1 (en) | Regulating the production of long chain hydrocarbons | |
CN111763685A (en) | PSY2 gene sequence related to synthesis of carrot carotenoid and application thereof | |
CN112795580B (en) | Pitaya gene HuAAE3 and application thereof in regulation and control of high temperature stress resistance of plants | |
CN111235168B (en) | Receptor kinase SlSRK2B participating in lycopene synthesis and application thereof | |
CN114196678A (en) | Hedgehog interacting protein OsHIPL1 gene for controlling rice seed vigor and engineering application thereof | |
CN108504665B (en) | Cauliflower internal reference gene and application thereof | |
CN117737026A (en) | GGPPS muteins related to carotenoid content in wheat kernel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |